Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study

por Leighl, N B, Bennouna, J, Yi, J, Moore, N, Hambleton, J, Hurwitz, H
Publicado 2011

Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung c...

por Krzakowski, M., Bennouna, J., Dansin, E., Kowalski, D., Hiret, S., Penel, N., Favrel, S., Tourani, J. M.
Publicado 2013

11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation

por van Halteren, H.K., Tan, A., Pellegrino, B., Brasiuniene, B., Bennouna, J., Cunquero-Tomás, A.J., Strijbos, M.
Publicado 2022

Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study

por Douillard, J Y, Lerouge, D, Monnier, A, Bennouna, J, Haller, A M, Sun, X S, Assouline, D, Grau, B, Rivière, A
Publicado 2001

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

por Conroy, T, Hebbar, M, Bennouna, J, Ducreux, M, Ychou, M, Llédo, G, Adenis, A, Faroux, R, Rebischung, C, Kockler, L, Douillard, J Y
Publicado 2010

Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

por Bennouna, J, Breton, J-L, Tourani, J-M, Ottensmeier, C, O'Brien, M, Kosmidis, P, Huat, T E, Pinel, M-C, Colin, C, Douillard, J-Y
Publicado 2006

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer

por Delord, J-P, Bennouna, J, Artru, P, Perrier, H, Husseini, F, Desseigne, F, François, E, Faroux, R, Smith, D, Piedbois, P, Naman, H, Douillard, J Y, Bugat, R
Publicado 2007

‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’

por Bennouna, J, Perrier, H, Paillot, B, Priou, F, Jacob, J H, Hebbar, M, Bordenave, S, Seitz, J F, Cvitkovic, F, Dorval, E, Malek, K, Tonelli, D, Douillard, J Y
Publicado 2006

Twelve ESMO Congress 2022 breakthroughs: practicing oncologists’ perceptions and potential application on presented data

por van Halteren, H.K., Bennouna, J., Brasiuniene, B., Tomas, A. J. Cunquero, Trinidad, A. M. Garcia, Indini, A., Liposits, G., Pellegrino, B., Popovic, L., Tan, A., Vidra, R., Strijbos, M.
Publicado 2023

Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial

por Melichar, B, Casado, E, Bridgewater, J, Bennouna, J, Campone, M, Vitek, P, Delord, J-P, Cerman, J, Salazar, R, Dvorak, J, Sguotti, C, Urban, P, Viraswami-Appanna, K, Tan, E, Tabernero, J
Publicado 2011

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

por Pons-Tostivint, E., Hulo, P., Guardiolle, V., Bodot, L., Rabeau, A., Porte, M., Hiret, S., Demontrond, P., Curcio, H., Boudoussier, A., Veillon, R., Mayenga, M., Dumenil, C., Chatellier, T., Gourraud, P. A., Mazieres, J., Bennouna, J.
Publicado 2023

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

por Pons-Tostivint, E., Hulo, P., Guardiolle, V., Bodot, L., Rabeau, A., Porte, M., Hiret, S., Demontrond, P., Curcio, H., Boudoussier, A., Veillon, R., Mayenga, M., Dumenil, C., Chatellier, T., Gourraud, P. A., Mazieres, J., Bennouna, J.
Publicado 2023

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic

por Girard, N., Greillier, L., Zalcman, G., Cadranel, J., Moro-Sibilot, D., Mazières, J., Audigier-Valette, C., Bennouna, J., Besse, B., Cortot, A., Couraud, S., Duruisseaux, M., Giroux-Leprieur, E., Toffart, A.-C., Westeel, V., Wislez, M.
Publicado 2020

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

por Samalin, E, Bouché, O, Thézenas, S, Francois, E, Adenis, A, Bennouna, J, Taieb, J, Desseigne, F, Seitz, J F, Conroy, T, Galais, M P, Assenat, E, Crapez, E, Poujol, S, Bibeau, F, Boissière, F, Laurent-Puig, P, Ychou, M, Mazard, T
Publicado 2014

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal

por Ott, P. A., Piha-Paul, S. A., Munster, P., Pishvaian, M. J., van Brummelen, E. M. J., Cohen, R. B., Gomez-Roca, C., Ejadi, S., Stein, M., Chan, E., Simonelli, M., Morosky, A., Saraf, S., Emancipator, K., Koshiji, M., Bennouna, J.
Publicado 2017

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study

por Girard, N., Galland-Girodet, S., Avrillon, V., Besse, B., Duruisseaux, M., Cadranel, J., Otto, J., Prevost, A., Roch, B., Bennouna, J., Bouledrak, K., Coudurier, M., Egenod, T., Lamy, R., Ricordel, C., Moro-Sibilot, D., Odier, L., Tillon-Strozyk, J., Zalcman, G., Missy, P., Westeel, V., Baldacci, S.
Publicado 2022

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

por Schuler, M., Yang, J. C.-H., Park, K., Kim, J.-H., Bennouna, J., Chen, Y.-M., Chouaid, C., De Marinis, F., Feng, J.-F., Grossi, F., Kim, D.-W., Liu, X., Lu, S., Strausz, J., Vinnyk, Y., Wiewrodt, R., Zhou, C., Wang, B., Chand, V. K., Planchard, D.
Publicado 2016

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

por Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.
Publicado 2021

Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year...

por Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., John, T.
Publicado 2021